CBD Co. Wants Counterclaims Nixed In Epidiolex Patent Row

By Sam Reisman · July 18, 2023, 3:58 PM EDT

British pharmaceutical firm GW Pharmaceuticals has urged a New Jersey federal judge to toss counterclaims lodged by InvaGen Pharmaceuticals in a patent dispute regarding GW's flagship CBD-derived epilepsy treatment Epidiolex....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Memorandum

Case Information

Case Title

JAZZ PHARMACEUTICALS RESEARCH UK LIMITED v. TEVA PHARMACEUTICALS, INC. et al

Case Number

Court

New Jersey

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

January 03, 2023

Recent Articles By Sam

June 04, 2024
FDA Advisers Rebuff Bid To Treat PTSD With MDMA
May 02, 2024
State Legislators Urge Feds To Change Cannabis' Status
April 18, 2024
FDA Head Gets GOP Rep.'s Rebuke Over Pot Rescheduling
April 11, 2024
Medical Cannabis Ads Are Lawful In Miss., 5th Circ. Told
April 03, 2024
Philly Injection Site Org. Isn't Religious, Judge Rules
April 01, 2024
Fla. High Court Says Voters Will Choose Whether To Legalize Pot
March 28, 2024
Romney Tells DEA Pot Review Must Heed Treaty Obligations
March 14, 2024
Cannabis Cos. Say Federal Position On Pot Is Irrational
January 30, 2024
Senate Dems Urge DOJ To Fully Decriminalize Marijuana
January 23, 2024
DOJ Seeks Dismissal Of Challenge To Federal Cannabis Ban